FIELD: chemistry.
SUBSTANCE: invention relates to dihydronaphthyridines and related compounds.
EFFECT: present invention provides the use of compounds which inhibit cKIT kinase across a wide range of c-KIT mutations, including complex occurrences of primary mutations (KIT exon 9 or 11) and secondary KIT mutations (exons 13, 14, 17 and 18) that may arise in a tumor cell line with resistant GIST.
8 cl, 3 tbl, 115 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS SUITABLE AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | 2018 |
|
RU2804468C2 |
| COMPOUND BASED ON DIHYDRONAPTHYRIDINONE, METHOD OF ITS OBTAINING, AND ITS USE IN MEDICINE | 2021 |
|
RU2809869C1 |
| ISOQUINOLINONE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH POLY(ADP-ribose)POLYMERASE-1, CONTAINING THEM AS ACTIVE INGREDIENT | 2020 |
|
RU2815480C1 |
| HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2015 |
|
RU2734390C2 |
| HER2 MUTATION INHIBITORS | 2022 |
|
RU2834124C2 |
| TRKA KINASE INHIBITORS, COMPOSITIONS BASED THEREON AND METHODS | 2015 |
|
RU2672583C2 |
| 2,3-DIHYDROQUINAZOLINE COMPOUNDS AS NAV1.8 INHIBITORS | 2020 |
|
RU2833870C2 |
| GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION CONTAINING IT AND A METHOD OF ITS PREPARATION | 2021 |
|
RU2800290C1 |
| SUBSTITUTED CARBONUCLEOSIDES DERIVATIVES USED AS ANTICANCER AGENTS | 2017 |
|
RU2712944C1 |
| NITROIMIDAZOLE DERIVATIVE AGAINST PULMONARY TUBERCULOSIS | 2016 |
|
RU2675622C1 |
